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Parkinson’s disease (PD) is an incurable progressive neurodegenerative disorder. Clinical
presentation of PD stems largely from the loss of dopaminergic neurons in the
nigrostriatal dopaminergic pathway, motivating experimental strategies of replacement
based on cell therapy. Transplantation of dopaminergic neurons derived from embryonic
stem cells significantly improves motor functions in rodent and non-human primate
models of PD. However, protocols to generate dopaminergic neurons from embryonic
stem cells generally meet with low efficacy and high risk of teratoma formation upon
transplantation. To address these issues, we have pre-treated undifferentiated mouse
embryonic stem cells (mESCs) with the DNA alkylating agent mitomycin C (MMC) before
transplantation. MMC treatment of cultures prevented tumorigenesis in a 12 week
follow-up after mESCs were injected in nude mice. In 6-OH-dopamine-lesioned mice,
intrastriatal injection of MMC-treated mESCs markedly improved motor function without
tumor formation for as long as 15 months. Furthermore, we show that halting mitotic
activity of undifferentiated mESCs induces a four-fold increase in dopamine release
following in vitro differentiation. Our findings indicate that treating mESCs with MMC
prior to intrastriatal transplant is an effective to strategy that could be further investigated
as a novel alternative for treatment of PD.
Keywords: embryonic stem cell, stem cell therapy, Parkinson model, mitomycin C, contrast-enhanced MRI
Introduction
Parkinson’s disease (PD) is an incurable progressive neurodegenerative disorder with
devastating consequences for patients and their families (Paulsen et al., 2013). Both genetic
and environmental elements play a role in its etiology, with aging as the major risk factor.
As the elderly population rises around the world, the number of affected individuals
increases accordingly (Lees et al., 2009). Pharmacological treatments provide adequate
symptomatic relief for many patients in the short term; however, severe adverse effects
develop over time and drugs fail to prevent disease progression (Obeso et al., 2010).
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Clinical presentation of PD stems largely from the loss
of dopaminergic neurons in the nigrostriatal pathway. Many
experimental strategies have therefore aimed to replace these
cells. In humans, transplantation of dopamine (DA) neurons
derived from fetal ventral mesencephalon has obtained clinical
success (Piccini et al., 1999; Freed et al., 2001), but use of such
neurons remains ethically controversial, besides the fact that
resources are limited.
Mesenchymal stem cells have been suggested as a potential
alternative source to fetal neurons (Khoo et al., 2011;
White, 2011). However, they fail to readily differentiate into
dopaminergic neurons, which has diminished the enthusiasm
for using such cells for PD therapy. Embryonic stem cells retain
the capacity to differentiate into DA neurons, both in vitro
and in vivo. Importantly, transplantation of embryonic stem
cell-derived DA neurons significantly improves motor functions
in rodent and non-human primate models of PD (Deacon et al.,
1998; Bjorklund et al., 2002; Muramatsu et al., 2009; Arenas,
2010; Kriks et al., 2011).
Several protocols have been described for differentiation of
embryonic stem cells into dopaminergic neurons, albeit with low
efficacy (Kirkeby et al., 2012; Sundberg et al., 2013). In addition,
the resulting cell population often contains serotoninergic
neurons, as well as residual undifferentiated embryonic cells that
have a strong potential to give rise to teratomas, thereby limiting
the clinical applicability of such cultures for transplantation
into patients (Kriks and Studer, 2009; Chung et al., 2011;
Lindvall, 2012). Moreover, published protocols are generally
expensive and time consuming, and fail to yield large amounts
of differentiated neurons, as required for clinical trials. Thus,
there is an urgent need for alternative strategies that are safe and
capable of generating purified embryonic stem cell-derived DA
neurons on a large scale.
In order to minimize technical issues and eliminate the
tumorigenic risk of transplanted cells, we tested for the first time
the use of fully undifferentiated embryonic stem cells treated
with the DNA alkylating and crosslinking agent mitomycin C
(MMC) as an alternative source for cell transplant in a PDmodel.
MMC is an FDA (2002)-approved chemotherapeutic agent for
pancreatic and gastric adenocarcinoma that has also been tested
in combination with other drugs in a wide variety of solid tumors
(Akhlaghpoor et al., 2012; Werner et al., 2013). Our findings
indicate that transplantation of undifferentiated embryonic stem
cells pre-treated with MMC is a safe and effective strategy,
and should be further investigated as a novel alternative for
treatment of PD.
Materials and Methods
Animals
All experiments were performed in accordance with
International Guidelines for the Care and Use of Mammals
in Neuroscience and Behavioral Research, and all procedures
were approved by the University Committee on Ethics of Animal
Use (protocol #DAHEICB060 for meningeal cell primary
culture and for stem cell transplantation, and #DAHEICB027
for teratoma assay and 6-OHDA lesion). Mice were housed
in self-ventilated cages (6 per cage) under standard laboratory
conditions (12 h light/dark cycle, food and water ad libitum).
Embryonic Stem Cell Culture
USP1 mouse embryonic stem cells (mESCs) transfected with
enhanced green fluorescent protein (eGFP) with retroviral
vector (Paulsen et al., 2011) were maintained on a cell-free
murine embryonic fibroblast-based substrate to avoid fibroblast
contamination between cell passages (Stelling et al., 2013). Cells
were maintained in D-MEM/F12 (Gibco) supplemented with
15% fetal bovine serum (JRH Biosciences), 2 mM glutamine
(Gibco), 0.1 mM non-essential amino acids (Gibco), 0.1
mM β-mercaptoethanol (Gibco), 40 µg/mL gentamicin sulfate
(Schering-Plough), and 0.2% of conditioned medium of CHO
(Chinese hamster ovary) cells producing leukemia inhibitory
factor (LIF).
Mitomycin C Treatment and Apoptosis Assay
For mitotic inactivation, undifferentiated mESC colonies were
treated for 12 h with different concentrations of MMC (1, 2.5,
5, or 10 µg/mL). Immediately after MMC treatment, apoptosis
was measured by the number of caspase 3 positive cells by flow
cytometry. After incubation with MMC, mESCs were washed
three times with D-MEM/F12, dissociated from the substrate
into a single-cell suspension with 0.25% trypsin-EDTA (Gibco-
Invitrogen) for 2 min, fixed with 4% paraformaldehyde in PBS
for 20 min, and permeabilized with 0.3% Triton X-100 for 5 min.
Cells were then blocked with 5% bovine serum albumin (BSA)
solution for 30 min and incubated for 3 h with primary anti-
mouse antibody against the active (cleaved) form of caspase
3 (Millipore), 1:400 in 1% BSA solution. Antibody-antigen
reaction was revealed by a secondary antibody conjugated to
Alexa Fluor 546, 1:1000 (Invitrogen). Acquisition was performed
using a fluorescence-activated cell sorting (FACS) Calibur flow
cytometer (Becton-Dickinson, USA) and data analysis was
performed usingWinMDI 2.8 software. A total of 100,000 events
were acquired from three independent experiments for each
tested MMC concentration.
In Vitro Neural Differentiation Over Meningeal
Cells
Dopaminergic differentiation was induced as described in
Hayashi et al. (2008). Meningeal cell cultures were prepared
from postnatal day 0 C57BL/6 mice. Briefly, the meninges
were dissected from the calvaria and cultivated in α-minimum
essential medium (MEMµ; Gibco-Invitrogen) containing 10%
fetal bovine serum (JRH Biosciences), penicillin G (40 U/mL),
and streptomycin (50 µg/mL). After the first passage, meningeal
cells were allowed to reach confluence and were used as a
feeder layer for mESCs. Mitomycin-treated and non-treated
mESC colonies were dissociated with 0.25% trypsin-EDTA
(Gibco-Invitrogen) for 2 min and plated on confluent meningeal
layers (200 cells/cm2). Co-cultures were maintained for
14 days in differentiation medium: G-MEM (Gibco-Invitrogen)
supplemented with 5% knockout serum replacement (Gibco-
Invitrogen), 2 mM glutamine, 0.1 mM non-essential amino
acids, 1 mM pyruvate, and 0.1 mM β-mercaptoethanol.
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Electrophysiological Recordings
Voltage-clamp recordings were made from neuron-like cells
14 days after co-culturing control or mitomycin-treated mESCs
eGFP positive cells on top of the meningeal cell layer.
Whole-cell currents were recorded through borosilicate glass
microelectrodes (WPI, USA) prepared on a P-97 horizontal
puller (Sutter Instruments, USA). Current signals were acquired
with an EPC-7 (HEKA, Germany) amplifier, low-pass filtered
at 1 kHz, and digitized at 10 kHz with a LabMaster interface
under the control of pClamp software (Axon Instruments, USA).
Extracellular recording solution contained (in mM): 165 NaCl, 5
KCl, 2 CaCl2, 10 dextrose, 5 HEPES, 2 NaOH, pH 7.35. Cells were
perfused at the rate of 1 mL/min at room temperature (23◦C)
throughout the recordings. The microelectrode (intracellular)
solution included (in mM): 80 CsCl, 80 CsF, 10 EGTA,
10 HEPES, and 26 CsOH, pH 7.30. Filled patch microelectrodes
had resistances ranging from 2.7 to 7.4 MΩ when measured in
the bath and a −7 mV liquid junction potential was added to
the reported clamp potentials. Membrane potential was held at
−70 mV and, approximately 2 min after achieving the whole-
cell configuration, voltage-sensitive currents were evoked by
200 ms depolarizing square pulses ascending in 10 mV steps
from −60 to +60 mV, preceded by a 10 ms hyperpolarization
to −90 mV. Leak-subtracted current traces were obtained by
the fractional method (P/4) using four scaled hyperpolarizing
subpulses. Data were analyzed using Clampfit 9 software (Axon
Instruments, USA).
Immunofluorescence for Dopaminergic Neurons
Following 2 weeks of neuronal differentiation, co-cultures
were fixed with 4% paraformaldehyde in PBS for 20 min,
permeabilized with 0.5% Triton X-100 for 5 min, blocked with
5% BSA for 60 min, and incubated overnight at 4◦C with
the primary antibodies mouse β-tubulin III (1:400, Sigma), or
rabbit anti-tyrosine hydroxylase (1:500, Millipore). Antibody-
antigen reaction was visualized using anti-rabbit Alexa-594- or
anti-mouse Alexa-594-coupled secondary antibodies (1:1000,
Invitrogen). Cell cultures were analyzed and images were
captured using a TCS SP5 laser confocal microscope (Leica
Microsystems).
Dopamine Release Assay
The amount of dopamine released spontaneously by mESC cells
into the conditioned medium for 48 h, or after stimulation
by elevated KCl solution, was measured by reverse phase
chromatography coupled with electrochemical detection (0.5 V),
as previously described (Arita et al., 2002). Cells were washed
twice in a low KCl solution (in mM: HEPES-NaOH, 20, pH
7.4; NaCl, 140; KCl, 4.7; CaCl2, 2.5; MgSO4,1.2; KH2PO4, 1.2;
glucose, 11) and incubated for 2 min in the same solution.
Cells were then incubated for 15 min in a high KCl solution
(in mM: HEPES-NaOH, 20, pH 7.4; NaCl, 85; KCl, 60;
CaCl2, 2.5; MgSO4, 1.2; KH2PO4, 1.2; glucose, 11) to promote
membrane depolarization. Briefly, 2 mL aliquots of culture
medium and 0.8 mL of low or high KCl solutions, from
control or mitomycin-treated differentiated mESCs, were first
submitted to the following purification steps: 50 mg alumina
(Al2O5) was weighed out in centrifuge tubes and the samples
were added to 1 mL Tris-buffer, pH 8.0, 103 mM EDTA,
plus 3 µL of 1 mM dihydroxybenzylamine (DHBA, internal
standard). The suspension was mixed for 10 min at 4◦C,
protected from light. Precipitated alumina was washed three
times with 1 mL of ultrapure water and dopamine was eluted
with 400 mL of 100 mM perchloric acid after 3 min of vortex
agitation. After centrifugation for 3 min at 1,000 × g, 100 µL
of medium and supernatant were analyzed. Isocratic separation
was obtained using a C18 reverse phase column (Supelco
4.6 × 250 mm, Sigma Aldrich) eluted with the following mobile
phase: 20 mM sodium dibasic phosphate, 20 mM citric acid,
pH 2.64, containing 10% methanol, 0.12 mM Na2EDTA, and
566 mg/L heptanesulfonic acid. Total time for sample analysis
was 30 min. Dopamine concentration was expressed as pg/g cell
protein. Pierce BCA Protein Assay Kit was used for total protein
quantification.
Teratoma Assay
To confirm the pluripotency of mESCs and the effectiveness
of the mitotic inactivation, mitomycin-treated or non-treated
undifferentiated mESCs (500,000 cells) were injected into the
thigh muscles of two-month-old nude immunodeficient mice
(six animals). After mitomycin treatment, mESC colonies
were washed three times with D-MEM/F12, dissociated
from the substrate into a single-cell suspension with 0.25%
trypsin-EDTA (Gibco-Invitrogen) for 2 min, and suspended in
400 µL of D-MEM/F-12. Using 27 gauge needles (Hamilton),
the left upper thigh was injected with control mESCs
(non-treated) and the right thigh with mitomycin-treated
mESCs (500,000 cells in 2 µL). Animals were continuously
monitored. Analgesic was added to the water bottle in order
to minimize pain and discomfort (ibuprofen suspension,
Abbott, 164 mg/L of drinking water). Twelve weeks after
injection, they were anesthetized and submitted to magnetic
resonance imaging (MRI, see below), then sacrificed to allow
for muscle dissection. Muscles from both hindlimbs were
fixed with 5% formalin, embedded in paraffin, and stained
with hematoxylin and eosin (HE) for histopathological
evaluation.
Magnetic Resonance Imaging of Teratomas and
Transplanted Animals
MRI was performed every 2 weeks after intrastriatal cell
injections in all experimental groups. Mice were premedicated
with atropine (0.2 mg/kg, s.c.) to reduce vagal tone and
then anesthetized with an intraperitoneal injection of ketamine
(90--120 mg/kg) and xylazine (10 mg/kg). Images were acquired
in a 7-T magnetic resonance scanner (MRI System 7T/210
ASR Horizontal Bore Magnet, Agilent Technologies). Brain
images were obtained using proton density (TR/TE: 10/2000 ms;
matrix: 128 × 128; slice thickness: 1 mm; no gap, 12 averages),
T1-weighted (TE/TR: 15/250 ms; matrix: 128 × 128; slice
thickness: 1 mm; no gap, 16 averages), and T2-weighted (TE/TR:
15/2563 ms; matrix: 128 × 128; slice thickness: 1 mm; no
gap, 14 averages) sequences in the axial, coronal, and sagittal
planes, before and after gadolinium injection (0.2 mL/Kg i.p.).
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Hindlimb images were obtained using proton density (TR/TE:
10/2000 ms; matrix: 128 × 128; slice thickness: 1 mm; no gap,
16 averages), T1-weighted (TE/TR: 15/800ms;matrix: 128× 128;
slice thickness: 1 mm; no gap, 5 averages), and T2-weighted
(TE/TR: 15/2563 ms; matrix: 128 × 128; slice thickness: 1 mm;
no gap, 14 averages sequences) in the axial, coronal, and sagittal
planes, before and after injection of 0.2 mL/kg gadolinium
(Mesentier-Louro et al., 2014).
Prior to image analysis, datasets were anonymized and
randomized across groups. Brain and hindlimb morphology and
tumor characteristics were evaluated in blinded fashion by two
experienced researchers and compared across groups. For each
dataset, all images were visually inspected for artifacts. Data
processing was performed using Osirix Software.1
6-OHDA-Induced Lesion and Transplantation
of mESCs
Neurotoxic injections into the dorsal striatum were carried out
according to a previously described protocol (da Conceição et al.,
2010). Briefly, after premedicated with atropine (0.2 mg/kg,
s.c.) and anesthetized with ketamine (90--120 mg/kg, i.p.) and
xylazine (10 mg/kg, i.p.), male Swiss mice received one unilateral
injection (2 µL) of 10 µg 6-OHDA (Sigma-Aldrich) dissolved in
0.9% sterile NaCl containing 0.1% ascorbic acid, at the rate of
0.5 µL/min (injection coordinates with respect to bregma were:
AP = +0.5 mm; L = −2.0 mm; DV = −3.0 mm). Following
the lesion, animals were allowed to recover for 4 weeks prior
to an initial behavioral assessment. After additional 4 weeks,
mice were re-anesthetized and 500,000 mitomycin-treated or
non-treated undifferentiated mESCs, suspended in 2 µL of D-
MEM/F12, were transplanted at the same coordinates. Lesion-
control animals were injected with culture medium only.
Behavioral Analysis
Mice from all experimental groups: lesion-control (n = 8),
untreated mESCs (mESC, n = 8), and mitomycin-treated mESCs
(MMC-mESC, n = 12), were behaviorally assessed every second
week, until 12 weeks after cell transplantation. The behavioral
paradigms employed were open field, cylinder, balance beam,
grip strength, and apomorphine-induced rotation tests, tested in
that order.
Spontaneous activity in the open field was evaluated with
the video-tracking EthoVision XT6 system (Noldus Information
Technology). After a habituation period, the mice were placed in
a 60 × 40 cm arena and locomotor activity, defined as the total
covered distance (cm), was evaluated for 5 min. The video was
recorded with a camera placed 1.0m above the observation arena.
Motor coordination deficits were measured by the number of
missteps and the latency to cross a 50 cm long, 2.5 cm in diameter
round wooden beam. All mice were pre-trained on the beam for
5 min in order to encourage rapid crossing without reversals or
stopping. Immediately after pre-training, animals were assessed
on the test beam.
Forelimb grip strength was assessed with a grip strengthmeter
with 1 g resolution (Insight EFF305, Brazil). Briefly, the mouse
1www.osirix-viewer.com
was allowed to grab a bar attached to a force transducer as it
was gently pulled by the tail horizontally away from the bar.
Force values from three consecutive trials with 5 s intervals were
averaged to determine grip strength for each mouse.
The cylinder test was performed as a measure of spontaneous
forelimb use (Schallert et al., 2000). Animals were placed
individually in a glass cylinder (11 cm diameter, 20 cm height)
and examined for spontaneous forepaw contact with the cylinder
wall. After each trial, the cylinder was thoroughly cleaned
with 70% ethanol. No habituation was allowed until a total
of 20 contacts were recorded per animal and only weight-
bearing wall contacts made by each forelimb on the cylinder
wall were scored. Data are presented as the percentage of
lesion/grafted forepaw contacts relative to the total number of
contacts, such that symmetric paw use would be scored as 50%
(10/20 contacts).
To investigate dysfunction in dopaminergic signaling,
analysis of apomorphine-induced rotation was performed as
described previously (da Conceição et al., 2010). Apomorphine
(0.5 mg/kg) was injected subcutaneously in the scruff and mice
were placed in an opaque cylinder 30 cm in diameter. After a
5 min period, full body rotations were manually recorded over
a period of 30 min, and data were expressed as net full body
turns per minute. Experimental groups were unknown for the
observer.
Histological Analysis
Four months after cell transplantation, mice were deeply
anesthetized and transcardially perfused with PBS followed by
4% PFA. Brains were post-fixed in 4% PFA for 24 h before
immersion in a standard sucrose gradient (10%, 20%, and
30%) until they sank. Brains were then embedded in OCT
medium (Tissue-Tek). Serial coronal 60 µm thick sections
were cut frozen on a cryostat (Leica) and collected in PBS.
Sections through the substantia nigra and striatum were
processed for immunohistochemistry. Sections were washed
with PBS, permeabilized in 1% Triton X-100 for 30 min,
incubated for 2 h with 3% H2O2 diluted in methanol, blocked
with 10% BSA for 3 h, and incubated overnight at 4◦C
with rabbit anti-TH primary antibody, 1:1000 (Millipore).
After PBS washing, sections were incubated for 2 h with
biotinylated anti-rabbit secondary antibody (Vector Labs, 1:200)
and staining was developed using ABC (Vectastain kit) and
DAB (Sigma) reactions. Neurons displaying a TH-positive
cytoplasm were counted as positive, and plotted throughout
the substantia nigra and the striatum using a motorized
Zeiss Axioplan microscope and the Neurolucida system (MBF
Bioscience).
Statistical Analysis
Numerical values and error bars are expressed as mean ± SEM
and mean ± SD for in vitro and in vivo measurements,
respectively. Tests for differences between means were
performed using a standard software package (GraphPad
Prism version 5.00), using a 5% significance level. In the
ANOVA procedures, Dunnet and Tukey tests were used for
group comparisons (Figures 1A, 4B–F, respectively). For
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FIGURE 1 | (A) Cytotoxicity of mitomycin C (MMC). Phase-contrast
micrographs showing the general morphology of control (A1) and MMC-treated
mESC colonies (A2--4). Cell death induced by treatment with increasing MMC
concentrations for 12 h (A5) was measured by flow cytometry as the
percentage of caspase 3 positive cells. At 1 µg/mL, the effect of MMC was not
significant (n = 3). (B) Assessment of neural differentiation in vitro: after 14 days
of co-culture onto meningeal cells, most GFP-mESCs (green) pre-treated with
MMC (1 µg/mL) became immunoreactive for β-tub III (B1, red) and TH (B2, red),
as expected for dopaminergic neurons. Scale bar: 20 µm. (C) Voltage-activated
currents from two neuron-shaped mESCs pre-treated with MMC and
differentiated for 14 days. Only the steps to −50, −30, −10, +10 (highlighted in
red), +30 and +50 mV are shown, for clarity. Most cells showed only outward
currents (C2) in response to depolarizing voltage steps (C1). One cell in 29
showed inactivating inward currents (C3). (D1) Representative chromatogram
of culture medium showing the dopamine peak, which increased with MMC
treatment, and the DHBA peak (internal standard). (D2) Differentiated mESCs
pre-treated with MMC released more dopamine to the culture medium
spontaneously over 48 h, as well as after 15 min incubation in 60 mM KCl,
compared to untreated cultures (* denotes p = 0.002 and p = 0.013,
respectively; Mann-Whitney’s test, n = 6).
the apomorphine-induced rotations (Figure 4A), treatments
were compared at each time point by a Bonferroni test of
inter-subject differences in a repeated measures ANOVA
procedure.
Results
Treatment with Mitomycin C Increased
Dopaminergic Differentiation in Vitro
We first determined the optimal concentration of MMC by
testing different concentrations in vitro and comparing cell death
rates to those observed in control cultures. We found that
1 µg/mL MMC was the maximal concentration of mitomycin
that did not induce apoptotic cell death compared to control,
untreated mESC cultures. Cultures treated with 1 µg/mL MMC
for 12 h were morphologically indistinguishable from untreated
controls (Figures 1A--5).
We next examined the effect of MMC pre-treatment
(1 µg/mL) on the ability of mESCs to differentiate into
neurons in vitro. After 14 days of co-culture with meningeal
cells in conditions promoting dopaminergic differentiation,
many MMC-treated mESCs developed neuron-like morphology,
and were immunoreactive for β-tubulin III (Figure 1B) and
tyrosine hydroxylase (Figure 1B). We first sought to evaluate
neuronal differentiation by determining whole-cell sodium
current densities. However, only one out of 29 MMC-treated
and none of 45 untreated neuron-like mESCs showed inward
voltage-activated currents (Figure 1C). We then analyzed
the dopaminergic phenotype by measuring neurotransmitter
release. Differentiated cultures that had been pre-treated with
MMC spontaneously released four times more dopamine than
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FIGURE 2 | Tumorigenicity assay in nude mice confirms efficacy of
MMC treatment. (A) Photograph of the hindlimbs from a nude mouse 12
weeks after intramuscular injection of 500,000 mitomycin-treated (right) and
untreated (left) mESCs. In all six animals tested, the right limbs were normal and
the left limbs displayed large tumors. (B) In vivo MRI scans, coronal plane,
proton density sequence, showing teratoma formation in the left limb, as
opposed to the right limb (which received mitomycin-treated mESCs) of the
same mouse. (C) In vivo MRI scans, axial plane, T1-weighted sequence,
showing enhancement of gadolinium-contrast signal (C2) in the teratoma
region. (D) High resolution photomontage of hematoxylin-eosin-stained section
through the leg injected with untreated mESCs, showing teratoma containing a
mixture of tissue types, including: (E) neural tube-like, (F) cartilaginous, and
(G) glandular-like (asterisks in (D) indicate enlarged regions in (E--G)). Scale bar:
1000 µm for (D); 100 µm for (E--G).
untreated cells (untreated: 4.16 ± 0.47 and MMC-treated:
16.59 ± 2.13 pg/µg protein over 48 h. Figure 1D). DA
release evoked by high KCl also increased about five times
after MMC treatment (untreated: 0.69 ± 0.10 and MMC-
treated: 3.55 ± 1.50 pg/µg protein after 15 min incubation in
60 mM KCl. Figure 1D). These results show that, although
the differentiating mESCs were not electrically mature at
14 days, 1 µg/mL MMC pre-treatment promoted a functional
dopaminergic phenotype, increasing both spontaneous and
stimulated neurotransmitter release.
Pre-treatment with 1 µg/mL Mitomycin C
Prevents Teratoma Formation by mESCs Grafted
into Nude Mice
Grafts of undifferentiated mESCs are prone to develop
into tumors, particularly teratomas, as expected from their
pluripotency (Fong et al., 2010). Standard protocols to assess
tumorigenesis consist of injecting cells into the sub-renal capsule,
the liver, the myocardium, the brain, or into subcutaneous
or intramuscular sites. We chose to administer intramuscular
injections into the hindlimb muscles because this is a
straightforward strategy known to be efficient for assessing
pluripotency capacity, besides being less harmful to the animal.
Additionally, this strategy allowed us to use each animal as its
own control by injecting control mESCs or MMC-treated cells in
each limb.
Twelve weeks after injection of 500,000 cells, all left hind
paws that received control cells developed prominent tumors,
revealing the proliferative capacity of mESCs (Figure 2A). In vivo
MRI confirmed formation of unilateral heterogeneous tumors
(Figure 2B). Tumors were also evidenced in transverse images
before (Figure 2C) and after gadolinium-contrast enhancement
(Figure 2C). Histopathological analysis (Figure 2D) revealed
that all tumors were mature teratomas containing ectodermal-
(Figure 2E) as well as endodermal- (Figure 2F) andmesodermal-
derived (Figure 2G) tissue, further confirming the pluripotency
of non-MMC-treated mESCs. Remarkably, the same number of
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FIGURE 3 | Transplantation of fully undifferentiated mESCs previously
treated or non-treated with MMC into 6-OHDA-lesioned mice brains.
(A) Survival curve of control and transplanted 6-OHDA-lesioned mice:
4 weeks after 6-OHDA injection in the striatum, mice were injected at the
same stereotaxic coordinates with culture medium (lesion-control, n = 8),
untreated mESCs (mESC, n = 8), or mitomycin-treated mESCs (MMC-
mESC, n = 12). (B,C) In vivo brain MRI, coronal plane, T1-weighted
sequence, prior to (left-hand panel) and after (right-hand panels)
gadolinium injection evidencing striatal tumor 4 weeks after transplantation
of untreated mESCs (B) and showing no signs of tumor formation in an
animal transplanted with 500,000 mitomycin-treated mESCs for as long as
60 weeks (C). (D) Computer-microscope reconstruction of a coronal
section through the forebrain of a 6-OHDA-lesioned mouse 4 weeks after
transplantation with untreated mESCs into the striatum (dots indicate cell
bodies positive for TH-immunostaining). (E) Histology of the boxed area in
the computer-generated plot in (D); boxed areas in E are shown at higher
magnification (F,G). (F) non-lesioned, non-transplanted side showing
control level of TH staining (brown) in the striatum. (G) 6-OHDA-lesioned
and mESC-grafted hemisphere, illustrating TH-positive cell bodies within
the host striatum in close proximity to the tumor edges. Scale bar:
1000 µm and 1800 µm, respectively, for (D), 500 µm for (E), 100 µm
for (F,G).
MMC-treated mESCs did not induce any tumor in the right
paws of the same animals (n = 6) (Figures 2A--C). These results
indicate that in vitro pre-incubation with 1 µg/mL MMC for
12 h completely blocked furthermitotic activity of graftedmESCs
in vivo.
Striatal Graft with Mitomycin C-Treated mESCs
Restores Motor Function in Hemi-Parkinsonian
Mice Without Teratoma Induction
To test for potentially beneficial effects of mESC transplantation
into a dopamine-deficient hemisphere and to investigate
whether MMC could prevent tumor formation in the living
brain, we injected MMC-treated pluripotent mESCs into
the striatum of mice that had been previously lesioned
by 6-OHDA. Every other week, transplanted animals were
weighed, underwent behavioral testing for motor function,
and were submitted to MRI scans to check for possible
formation of brain tumors and to assess blood--brain barrier
integrity. As expected, unilateral striatal lesion consistently
resulted in severe motor dysfunction, but was not lethal per
se. However, animals that received intrastriatal transplants of
500,000 untreated mESCs died between 3 and 7 weeks later
(Figure 3A). In all animals from this group, intracerebral
tumors were revealed by 7 Tesla MRI scans as early as
05 days after mESC transplant (Figure 3B). Importantly, contrast
in intracerebral tumor images was significantly enhanced
after gadolinium injection, further indicating a disruption of
the integrity of the blood--brain barrier in these animals
(Figure 3B, right). Post-mortem histological analysis with
HE staining of all 8 transplanted hemispheres confirmed
the presence of solid tumors after transplantation with
untreated mESCs. In addition, immunohistochemistry for
TH (Figures 3E--G) and computer-microscope reconstruction
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FIGURE 4 | Functional recovery after transplantation of fully
undifferentiated mESCs treated with MMC. (A) Rotational behavior induced
by apomorphine (0.5 mg/kg i.p.) in 6-OHDA-lesioned mice. Eight weeks after
the 6-OHDA lesion, mice received intra-striatal injections of culture medium
(lesion-control, black), untreated 500,000 mESCs (blue), or 500,000
mitomycin-treated mESCs (MMC-mESC, red). After 12 weeks, all animals
transplanted with mitomycin-treated mESCs were alive and had greatly reduced
signs of striatal lesion, approaching the performances of normal healthy animals
in the different tasks. Motor coordination on the balance beam test was
assessed by the number of slips (B) and the latency to cross (C) a 50 cm long
beam. (D) Spontaneous locomotor activity in the open field was tracked and
expressed as the distance covered within 5 min. (E) Forelimb grip strength was
measured as the maximal pull force on a bar. (F) Forelimb use during vertical
exploratory behavior was measured in the cylinder test, in which normal animals
most often touched the cylinder wall with both forepaws when rearing. Values
are means ± SD. In (A), (*) denotes p < 0.01 vs. lesion control; in (B--F) (*)
denotes p < 0.01 vs. normal and (#) denotes p < 0.01 vs. lesion controls in
post-ANOVA tests.
(Figure 3D) revealed a population of dopaminergic cell
bodies restricted to the injected striatum (dots indicate cell
bodies positive for TH-immunostaining). In contrast, all
animals receiving MMC-treated mESCs survived until the
end of the observation period of 12 weeks post-transplant
(n = 12 mice; Figure 3A), and no tumors could be detected
in contrast-enhanced MRI scans (Figure 3C) or through
histopathological investigation. Four additional MMC-mESC
transplanted mice were monitored for as long as 60 weeks with
no signs of pathology.
All animals lesioned by unilateral intrastriatal 6-OHDA
injection developed motor signs of dopamine deficiency that
were stable after four weeks, as previously described (Iancu
et al., 2005). At this time point, the rate of apomorphine-
induced contralateral full-body rotations ranged from 15 to
20 rpm amongst all 6-OHDA lesioned animals. For ease of
comparison, rotation rates for each experimental group were
normalized relative to the average rate measured on the week
of transplantation (week 0). 6-OHDA-lesioned mice injected
with culture medium (6-OHDA + medium, n = 8) maintained
a steady behavioral response to apomorphine, displaying
0.98± 0.19 relative rpm at 20 weeks after the lesion (Figure 4A).
Transplantation with untreated mESCs (6-OHDA + mESCs,
n = 8) led to a marked reduction in the rate of apomorphine-
induced rotations, before generating brain tumors that eventually
killed the animals. Mice transplanted with MMC-treated mESCs
(6-OHDA +MMC-mESCs, n = 12) displayed a slower but steady
decrease in the number of apomorphine-induced rotations,
reaching 0.13 ± 0.11 relative rpm 12 weeks after transplant
(Figure 4A). Already at 2 weeks after transplant, the difference
relative to 6-OHDA + medium control animals was significant
(p< 0.001, Bonferroni test in RM ANOVA).
Long-term motor improvements resulting from
MMC-treated mESC were further assessed 12 weeks after
transplantation using open field, grip strength, beam walking,
and cylinder tests. To assess the extent of recovery from
the initial lesion, behavioral scores were compared across
6-OHDA + medium control, 6-OHDA + MMC-treated
mESC, and healthy, non-lesioned, non-transplanted, aged-
matched mice (normal group, n = 8). Locomotor activity in
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FIGURE 5 | Schematical summary of the research approach.
the open field arena (measured as the distance covered by
the animal over 5 min) was reduced by 39% on average in
6-OHDA + medium animals compared to healthy normal mice
(normal: 2415 ± 373 cm; 6-OHDA + medium: 1468 ± 187 cm),
but only by 17% in 6-OHDA + MMC-treated mESC animals
(2003 ± 196 cm; Figure 4D). In the beam walking test for fine
motor coordination and balance, 6-OHDA + medium mice
slipped approximately three times as often (6.5 ± 1.8 slips,
Figure 4B) and took twice the time to cross the 50 cm beam
(11.3 ± 0.8 s, Figure 4C) as did healthy normal mice (2.0 ± 1.1
slips and 5.9 ± 1.5 s crossing time, respectively). Animals
injected with 6-OHDA + MMC-treated mESCs displayed a
significant improvement, so that both measures approached
normal levels 12 weeks after transplant (2.6 ± 0.9 slips and
7.6 ± 1.9 s crossing time). None of the animals tested fell while
crossing the beam. Forelimb grip strength was markedly reduced
in 6-OHDA + medium mice (46.8 ± 13.1 g) as compared with
healthy normal mice (123.0 ± 21.0 g), but 6-OHDA + MMC-
mESC transplanted animals completely recovered muscle
strength (146.9 ± 36.7 g; Figure 4E). Finally, 6-OHDA + MMC-
treated mESC transplanted hemi-parkinsonian mice behaved
almost like healthy mice regarding symmetric forelimb use
in the cylinder test (normal: 66.3 ± 7.4% and MMC-mESC:
71.1 ± 13.6% double contacts, respectively; Figure 4F), whereas
6-OHDA + medium mice made significantly fewer symmetric
contacts with the cylinder wall (16.1 ± 5.4%), indicating marked
motor asymmetry. Our data show that MMC-treated mESC
transplant induced considerable recovery of motor function in
a mouse model of Parkinsonism, without any signs of tumor
formation for up to 15 months following transplant.
Discussion
In the present study, we show that transplantation of mESCs,
pre-treated with the FDA-approved chemotherapeutic agent
MMC, in the 6-OHDA-lesioned mouse model of Parkinson’s
disease resulted in significant improvement in motor function
and reduced akinesia without tumor formation. Furthermore,
we show that halting mitotic activity of undifferentiated mESCs
induced a four-fold increase in the release of dopamine after in
vitro differentiation (Figure 5).
A central concern related to the therapeutic use of pluripotent
stem cells in PD is the eradication of non-dopaminergic
neurons and, especially, of residual stem cells with tumorigenic
potential (Sykova and Forostyak, 2013). Additionally, most
available studies use time-consuming protocols requiring
multiple steps for generation of a limited number of DA
neurons in vitro (Lindvall, 2012). Also, it is not fully
understood whether in vitro-derived neurons are able to
maintain their functional properties after in vivo transplantation
(Park et al., 2006). All these caveats limit translation of this
approach to the clinical practice. As shown in this study, the
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use of fully undifferentiated mESCs may represent a novel
alternative.
Undifferentiated mESCs are easier to maintain than
differentiated cultures; they are less expensive to cultivate
and easier to obtain on a large scale. We have recently
developed a method to cultivate human embryonic stem
cells on suspended beads combined with the use of stirred
microcarrier systems, with an optimized xeno-free culture
medium (Marinho et al., 2013). Using this protocol, it is possible
to produce over 160 million pluripotent cells per week, providing
a step forward towards therapeutic use of human embryonic
stem cells.
Much attention has been given to the benefits of using
autologous induced pluripotent stem cells (iPSCs) instead of
embryonic stem cells in preclinical and clinical studies. However,
Araki et al. (2013) have shown that iPSCs and embryonic
stem cells share similar limited immunogenicity. Importantly,
undifferentiated embryonic stem cells are less immunogenic
than their differentiated derivatives (Bonde and Zavazava,
2006).
Recently, several protocols for cell purification have been
proposed as alternatives to eliminate potential tumorigenic
cells (Kahan et al., 2011; Sundberg et al., 2013) or to obtain
highly enriched populations of dopaminergic neurons (Pruszak
et al., 2007; Bernstein and Hyun, 2012), without the need
for genetic manipulation of cells. Thus, magnetic (MACS)
or fluorescence-activated cell sorting (FACS), associated with
the use of antibodies against specific cell surface marker
antigens (generally, clusters of differentiation markers), have
been incorporated as important tools for transplantation studies.
However, cell sorting procedures are not fully efficient, besides
the fact that such multi-step techniques may compromise
the viability of fragile neuronal cell types (Emre et al.,
2010).
MMC is a DNA-alkylating agent that irreversibly blocks cell
division, inducing arrest mainly in the S phase of the cycle (Witte
and Bradke, 2008). Acting as a DNA crosslinking agent, MMC
could potentially be genotoxic to stem cells. Vinoth et al. (2008)
investigated how genotoxic stress caused by MMC affects human
embryonic stem cells as compared to a somatic human fetal lung
fibroblast cell line, and found a 10% increase in the number of
aberrant somatic cells vs. a 5% increase in human embryonic
stem cells, indicating that the latter are more resistant to MMC-
induced damage.
Due to its cytotoxic activity, we tested the impact of MMC
pre-treatment on the viability and differentiation potential of
mESCs. Most mESCs pre-treated with MMC and co-cultured
onto a feeder layer of meningeal cells for neuronal induction
exhibited typical neuronal morphology and expressed β-tubulin
class III and TH. Interestingly, pre-treated cells released
five times more dopamine, as compared to non-treated
ones. These results indicate that MMC treatment promotes
mESC differentiation towards a functional dopaminergic
phenotype. Using a different cell type and experimental
approach, Felfly et al. (2011) showed that MMC alone trigger
the expression of several differentiation genes in murine neural
stem cells.
To investigate the intrinsic tumorigenic capacity of
pluripotent stem cells, we tested if MMC treatment blocks
teratoma formation. Results with nude mice showed that
pre-treatment of cells with 1 µg/mL MMC for 12 hours
suppressed the tumorigenic capacity of transplanted mESCs
after least 12 weeks. Untreated mESCs transplanted in the
opposite hindlimbs of the same animals generated large
teratomas.
As might be expected, mice injected in the striatum with non-
treated mESCs developed tumors and exhibited blood–brain
barrier disruption, as assessed by periodic MRI scans, which
may explain why none of those animals survived more than
seven weeks after transplantation. Nonetheless, despite the
presence of intracerebral teratomas, all animals that received
non-treated mESCs performed better on the apomorphine-
induced rotation test. We suggest that this effect may be due
to the differentiation of transplanted mESCs into dopaminergic
neurons in vivo. In support of this notion, Felfly et al. (2011)
described grafts able to generate DA neurons, which were
surrounded by glial cells from the host, suggesting that neural
differentiation of transplanted cells may be influenced by glial
signaling in vivo. Moreover, mesencephalic neuroepithelial stem
cells differentiated into tyrosine hydroxylase-positive neurons
3 times more efficient when transplanted into the brain of PD
brains than in controls, which could also be explained by the
presence of environmental cues (Mine et al., 2009). Finally,
Takagi et al. (2005) demonstrated that FGF20, preferentially
expressed by cells within the substantia nigra, increases the
differentiation of DA neurons from ESC-derived neurospheres
in monkeys.
Transplantation of MMC-treated mESCs in the brain of
6-OHDA lesioned animals significantly reduced the rate of
apomorphine-induced rotations and nearly normalized motor
performance at 12 weeks post-transplant. However, the beneficial
effect of transplantation was somewhat slower in these animals
than in mice transplanted with non-treated cells. This lies
in apparent contradiction with our in vitro data showing
higher spontaneous and stimulated dopamine release from
differentiated MMC-treated mESCs. Nevertheless, untreated
mESCs obviously proliferated faster, maybe generating more
dopaminergic cells than MMC-treated mESCs. It will be of
interest to assess whether survival, differentiation, and tissue
integration are directly affected by prior MMC treatment such
as proliferation.
In conclusion, results presented here show that MMC
treatment allowed pluripotent stem cells to restore motor
function without forming tumors for as long as 15 months
in mice, suggesting that MMC-treated undifferentiated
embryonic stem cells should be further investigated as a
safe and effective strategy for the treatment of Parkinson’s
disease.
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